На главную
Видео добавленное пользователем “OncLiveTV”
Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations
Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.
Просмотров: 4691 OncLiveTV
Screening for and Treating Iron Overload
Thomas D. Coates, MD, offers his perspective on monitoring patients who are at risk for chronic iron overload and treating those who have been diagnosed.
Просмотров: 2842 OncLiveTV
Nivolumab in Non-Small Cell Lung Cancer
In this segment, H. Jack West, MD, discusses the dramatic benefit seen by some patients with non-small cell lung cancer who receive treatment with nivolumab. For more from this discussion, visit http://www.onclive.com/peer-exchange/nsclc-needs
Просмотров: 6227 OncLiveTV
Iron Chelation Therapy Options in Iron Overload
Thomas D. Coates, MD, outlines some of the ways in which excess iron can be removed from the body, which includes initiating iron chelation therapy.
Просмотров: 2465 OncLiveTV
Dr. Jagannath on Life Expectancy in Multiple Myeloma
Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma. For more hematology resources: http://www.onclive.com/specialty/hematologic-cancer
Просмотров: 6716 OncLiveTV
Selecting First-Line Treatment for Chronic Lymphocytic Leukemia (CLL)
Moderator Myron Czuczman, MD, leads experts in a discussion about selecting first-line therapy for varied subgroups with CLL, and recognizing the shift from the traditional chemotherapy regimens to the incorporation of newly approved anti-CD20 antibodies.
Просмотров: 6436 OncLiveTV
Enzalutamide? Abiraterone? Neither?
Dr. Leonard Gomella talks about when he would choose to use abiraterone or enzalutamide for his metastatic prostate cancer patients. The AR-V7 spice variant as a marker for resistance against these drugs is an exciting new development! View more, at http://www.onclive.com/inside-oncology
Просмотров: 3778 OncLiveTV
Managing Follicular Lymphoma
Brad S. Kahl, MD, and Richard R. Furman, MD, explain the management of follicular lymphoma.
Просмотров: 3548 OncLiveTV
Treatment of Neuroendocrine Tumor Liver Metastases
Rodney F. Pommier, MD, discusses surgical debulking and embolization for the treatment of hepatic metastases in patients with pancreatic neuroendocrine tumors. To view more from this discussion, visit http://www.onclive.com/peer-exchange/pancreatic-nets
Просмотров: 6905 OncLiveTV
The Use of Novel PI3K Inhibitors in CLL
Jennifer R. Brown, MD, PhD, reviews the data from the phase III DUO trial of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia.
Просмотров: 1549 OncLiveTV
CAR T-Cell Therapy for Multiple Myeloma
Keith Stewart, MB, ChB; Saad Z. Usmani, MD; Thomas G. Martin, MD; Sagar Lonial, MD; Ivan M. Borrello, MD; and Gareth Morgan, MD, PhD, highlight trials that are reviewing the potential use of chimeric antigen receptor T-cell therapy that targets the protein, B-cell maturation antigen in multiple myeloma.
Просмотров: 1908 OncLiveTV
When to Suspect Sarcoma
Panelists William D. Tap, MD; Damon Reed, MD; George D. Demetri, MD; Martee L. Hensley, MD; Mark Agulnik, MD; and Shreyaskumar Patel, MD, discuss the challenges in determining an accurate diagnosis and treatment approach in soft tissue sarcoma, as well as the most common and most aggressive soft tissue sarcoma subtypes.
Просмотров: 12447 OncLiveTV
Biology of Head and Neck Squamous Cell Carcinoma
In this segment, Robert L. Ferris, MD, PhD, FACS and Ezra Cohen, MD, examine the underlying biology of head and neck cancers.
Просмотров: 3188 OncLiveTV
Amy Robach on Factors Impacting Her Breast Cancer Treatment Decision
Amy Robach, breast cancer survivor and Good Morning America news anchor, discusses her choice to have a bilateral mastectomy against the advice of her surgical oncologist.
Просмотров: 6096 OncLiveTV
Extended Aromatase Inhibitor Risk/Benefit
Hope S. Rugo, MD, and Ruth O’Regan, MD, discuss the toxicities, risk/benefit profile, and side effects of extended aromatase inhibitors in breast cancer.
Просмотров: 1073 OncLiveTV
Differences Among PARP Inhibitors in Ovarian Cancer
Panelists Bradley J. Monk, MD; Thomas Herzog, MD; Robert L. Coleman, MD; Kathleen N. Moore, MD; and Angeles Alvarez Secord, MD, discuss the data for niraparib, the emerging PARP inhibitor, in advanced ovarian cancer.
Просмотров: 3665 OncLiveTV
When to Initiate Treatment for ITP
In this segment, Howard A. Liebman, MD; Keith McCrae, MD; and Ivy Altomare, MD, explain how determining when to treatment idiopathic thrombocytopenia purpura (ITP) involves more than simply reading a number.
Просмотров: 3503 OncLiveTV
Long-Term Results for Immunotherapy in Melanoma
Panelists Jeffrey S. Weber, MD, PhD; Georgina Long, MD, PhD; Jason J. Luke, MD; Robert H.I. Andtbacka, MD, CM; and Michael A. Davies, MD, PhD, discuss the data looking at long-term use of CTLA-4 and PD-1 antibodies in metastatic melanoma and the implications for outcomes after stopping therapy.
Просмотров: 3444 OncLiveTV
Adverse Events of Ibrutinib in Chronic Lymphocytic Leukemia
In this segment, Jennifer Brown, MD, and Richard Furman, MD, review adverse events associated with ibrutinib therapy in the treatment of chronic lymphocytic leukemia (CLL).
Просмотров: 6389 OncLiveTV
Case Study: Treating Metastatic Triple-Negative Breast Cancer
In the final case study of the discussion, panelists describe the treatment of a 58 year-old Caucasian woman with metastatic triple-negative breast cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/MBC-challenges
Просмотров: 2587 OncLiveTV
Duration of Immunotherapy in Melanoma
Keith Flaherty, MD; Jason Luke, MD, FACP; Rene Gonzalez, MD; and Jeffrey Weber, MD, PhD, review data concerning optimal melanoma treatment duration for immunotherapy agents.
Просмотров: 3125 OncLiveTV
Dr. Rosenberg Discusses the Curative Potential of Cancer Immunotherapy
Steven A. Rosenberg, MD, PhD, Chief of Surgery, National Cancer Institute, Professor of Surgery, Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences, Giant of Cancer Care, discusses the curative potential of cancer immunotherapy.
Просмотров: 2067 OncLiveTV
Treatment with Radioactive Iodine
Michael Tuttle, MD and Matthew Taylor, MD describe the risk stratification approach for use of radioactive iodine on the endocrine and nuclear medicine side of thyroid cancer.
Просмотров: 4318 OncLiveTV
Diagnosis and Initial Treatment of Medullary Thyroid Cancer
In this segment, panelists discuss the diagnosis and primary treatment for patients with medullary thyroid cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/thyroid-cancer
Просмотров: 2346 OncLiveTV
Dr. Luke Discusses the Controversy Surrounding Ipilimumab/Nivolumab Combo in Melanoma
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the controversy surrounding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma, which was explored in the CheckMate-067 trial, during the AACR Annual Meeting.   The combination gained regulatory approval based on response rate and progression-free survival, with the assumption that those results would translate to overall survival (OS), Luke explains. Results of the CheckMate-067 study, reported at AACR, confirmed there was a 12% improvement in OS, however, there is still a question of whether the OS improvement justifies the extreme increase in toxicity with the addition of ipilimumab, relative to PD-1 monotherapy.   While doctors continue to have differing opinions on the subject, Luke says his group is interested in exploring how to maximize benefit and minimize toxicity. One possible way to do this is with IDO inhibitor combinations, Luke says, for example, leading in with a PD-1 combination with high efficacy and low toxicity, and then using a CTLA-4 or ipilimumab-based regimen in the second-line setting if a patient progresses.
Просмотров: 1411 OncLiveTV
Colorectal Cancer: FOLFOX versus FOLFIRI in the MAVERICC Trial
The panelists, John L. Marshall, MD; Johanna Bendell, MD; Charles S. Fuchs, MD, MPH; Tanios Bekaii-Saab, MD; and Richard Kim, MD, discuss how they decide between the chemotherapy regimens FOLFOX and FOLFIRI in colorectal cancer.
Просмотров: 3111 OncLiveTV
Immunotherapy and MSI Status in Colorectal Cancer
The panelists, John L. Marshall, MD; Johanna Bendell, MD; Tanios Bekaii-Saab, MD; Charles S. Fuchs, MD, MPH; and Richard Kim, MD, discuss the value of microsatellite instability (MSI) testing and access to appropriate treatment in colorectal cancer.
Просмотров: 1851 OncLiveTV
Liver Resectability in Metastatic Colorectal Cancer
Marwan Fakih, MD, outlines several factors to consider when determining the appropriateness and feasibility of liver resectability.
Просмотров: 712 OncLiveTV
Splenectomy in Idiopathic Thrombocytopenic Purpura
In this segment, Howard A. Liebman, MD; Ivy Altomare, MD; and Keith McCrae, MD, explain the use of splenectomy as a treatment for idiopathic thrombocytopenic purpura (ITP).
Просмотров: 1793 OncLiveTV
Chemotherapy for Metastatic Breast Cancer in 2017
Mark Pegram, MD, and Joyce O’Shaughnessy, MD, discuss the historic perspective on chemotherapy and sequential single-agent use of chemotherapy for advanced breast cancer.
Просмотров: 3327 OncLiveTV
Dr. Andre Goy Explains Marginal Zone Lymphoma
Просмотров: 1574 OncLiveTV
Nivolumab Plus Ipilimumab in Advanced Melanoma
In this segment, panelists discuss immunotherapy combinations that have generated excitement as treatments for patients with melanoma, specifically those looking at the PD-1 and CTLA-4 inhibitors. To view more from this discussion, visit http://www.onclive.com/peer-exchange/metastatic-melanoma
Просмотров: 3853 OncLiveTV
Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia
In this segment, the panelists discuss whether or not the administration of BCR-ABL-targeted TKIs should ever be stopped for patients with CML experiencing a complete molecular response. To view more from this discussion, visit http://www.onclive.com/peer-exchange/mds-cml
Просмотров: 3483 OncLiveTV
Accurately Diagnosing the Soft Tissue Sarcoma
Brian Van Tine, MD, PhD, leads the discussion about the diagnostic workup of a new patient, the usefulness of imaging and genetic testing, and the importance of multidisciplinary care. A good history and physical is the most important test we order, according to Lor Randall, MD, FACS.
Просмотров: 5281 OncLiveTV
Niraparib Maintenance Therapy for Ovarian Cancer
Panelists Bradley J. Monk, MD; Angeles Alvarez Secord, MD; Robert L. Coleman, MD; Thomas Herzog, MD; and Kathleen N. Moore, MD, outline the clinical evidence for the use of the PARP inhibitor, niraparib, in advanced ovarian cancer.
Просмотров: 1639 OncLiveTV
MDS: Understanding Disease Characteristics and Progression
James M. Foran, MD, FRCPC, and Azra Raza, MD, discuss the common disease characteristics with MDS and drivers of disease progression.
Просмотров: 1261 OncLiveTV
Melanoma: BRAF/MEK Targeted Therapy
Panelists Keith T. Flaherty, MD; Georgina Long, BSc, MBBS; Jason J. Luke, MD; and Jeffrey S. Weber, MD, describe the use of dual targeted therapies, including BRAF/MEK inhibition therapies and their effects on long-term survival.
Просмотров: 1124 OncLiveTV
Treatment of HER2-Positive Breast Cancer
In this segment, Joyce O’Shaughnessy, MD; Debu Tripathy, MD; and Edith Perez, MD, review treatment options of human epidermal growth factor receptor (HER)-2-positive breast cancer.
Просмотров: 3736 OncLiveTV
Ablation vs Resection in Liver Cancer
Panelists Richard S. Finn, MD, and Richard H. Marshall, MD, discuss patient selection criteria for ablation techniques versus resection in liver cancer and the expanding role of radiofrequency ablation.
Просмотров: 879 OncLiveTV
Diffuse Large B-Cell Lymphoma (DLBCL) Regimens
Brad S. Kahl, MD, and Richard R. Furman, MD, describe chemotherapy regimens used in the management of diffuse large B-cell lymphoma.
Просмотров: 1909 OncLiveTV
Obinutuzumab: Effective, Safe, and Worth the Cost?
Panelists discuss the use of obinutuzumab, including the results of the CLL 11 clinical trial, early experiences with patient response, and side effects.
Просмотров: 2970 OncLiveTV
Dr. Liu on Medical Advancements for Neuroendocrine Tumors
Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.
Просмотров: 1375 OncLiveTV
Case Study: Treating Papillary Thyroid Cancer
Marcia S. Brose, MD, PhD, presents a case study focused on a women diagnosed with papillary thyroid cancer at age 35 who went on to receive systemic therapy. For more from this discussion, visit http://www.onclive.com/peer-exchange/thyroid-cancer
Просмотров: 2780 OncLiveTV
Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer
Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Просмотров: 892 OncLiveTV
The Impact of Lymphedema in Patients With Head and Neck Cancer
Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.
Просмотров: 1020 OncLiveTV
Dr. White on Omitting Radiation in Breast Cancer
Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the omission of radiation therapy for patients with breast cancer. Omitting radiation in this space requires finding a population of patients that has a low enough overall risk following lumpectomy, says White. The omission of radiation will leave patients with a slightly higher locoregional recurrence risk than if they had been radiated or had undergone a mastectomy. The omission of radiation in younger patients with breast cancer. This is a bit harder, says White, because there are some subgroups of patients that can have quite high recurrence risks. Biologic selection criteria can be used along with the basic, clinical pathologic criteria to find a group of patients who may, indeed, have a slightly higher risk of local recurrence, but whose overall survival will not be significantly affected.
Просмотров: 1134 OncLiveTV
Understanding Drivers of Progression in Myelofibrosis
Srdan Verstovsek, MD, PhD, and Daniel J. DeAngelo, MD, PhD, discuss heterogeneity and progression in myelofibrosis, including disease characteristics, rapid progression, and morbidity and mortality.
Просмотров: 2045 OncLiveTV
Treatment With Eribulin in Metastatic Breast Cancer
Joanne Blum, MD, PhD, and Adam Brufsky, MD, PhD, discuss eribulin as a treatment of patients with metastatic breast cancer. For more expert insight, visit http://www.onclive.com/insights/evolution-metastatic-breast-cancer
Просмотров: 1085 OncLiveTV
Is the PD-L1 Biomarker Ready for Prime Time?
The panel discusses the current status of using PD-L1 as a predictive biomarker for anti–PD-1 therapy. The hope is that an optimized biomarker will be sorted out now that the drugs are becoming available for patients.
Просмотров: 1309 OncLiveTV
Managing Brain Metastases in Breast Cancer
Managing Brain Metastases in Breast Cancer
Просмотров: 1036 OncLiveTV